Latest Kidney Cancer News
Various Neurological Complications Tied to Anti-PD-1 Therapy
The researchers found that 2.9% of the 347 patients treated with anti-PD-1 monoclonal antibodies developed subacute onset of neurological complications.
FDA Approves First Biosimilar for Kidney Cancer Treatment
Mvasi, which is approved to treat colorectal, lung, brain, kidney, and cervical cancer, was found to be biosimilar to the drug Avastin.
Immunotherapy Superior to Sunitinib for Front-Line mRCC Treatment
Checkpoint inhibitor combination of nivolumab plus ipilimumab improved progression-free and overall survival compared with sunitinib.
Upfront Cabozantinib for Advanced RCC Improves Outcomes
Cabozantinib reduced the risk of disease progression or death compared with sunitinib among patients with previously untreated advanced renal cell carcinoma.
Early NLR Changes Predict mRCC Immunotherapy Outcomes
Rises and decreases in neutrophil-to-lymphocyte ratio at 6 weeks after treatment with anti-PD-1/PD-L1 immune checkpoint blockade is associated with progression-free and overall survival.
Energy Dense Diet Increases Obesity-Related Cancer Risk
The increased risk for obesity-related cancer was seen among women who were normal weight at enrollment.
Geriatric Consultation Uncommon in Kidney Cancer Surgery
Participant age and comorbidity burden appeared to be consistent determinants of use of services, although hospital-level variation was also noted.
Targeted Multigene Panel Testing Useful for Hereditary Kidney Cancer
The most commonly altered genes were folliculin and fumarate hydratase in 1.8% and 1.3%, respectively.
Type of Long-term Response to Targeted mRCC Therapy Affects Outcomes
Patients who have a complete response to 2 or more years of anti-VEGF treatment have the best progression-free and overall survival.
BMI, Belly Fat Suggest Obesity-Related Cancer Risk
BMI and location of excess body fat on the body are good indicators of obesity-related cancer risk.
Renal, Bladder Cancer Linked to Physical Inactivity
Renal and bladder cancer patients were, respectively, 77% and 73% more likely to report lifetime physical inactivity than controls without cancer.
AUA Releases Updated Renal Mass Guidelines
The document spells out in greater detail the criteria for radical and partial nephrectomy and for placing patients on active surveillance.
Early CRP Response to mRCC Drugs Predicts Survival
Changes in C-reactive protein levels 4 weeks after starting sunitinib or sorafenib treatment are associated with overall and progression-free survival.
AS Safe for Cystic Renal Masses in Selected Patients
In a single-center study, 24% of patients crossed over to treatment and 95% of patients were alive after 5 years of follow-up.
RCC Patients May Benefit from Nivolumab After Disease Progression
Nivolumab treatment beyond disease progression results in reductions in tumor burden, study finds.
Renal and Urology News Articles
- Immunotherapy Superior to Sunitinib for Front-Line mRCC Treatment
- Pruritus in Hemodialysis Patients Underestimated, Undertreated
- Anagliptin Improves LDL Partly Via ApoB-100 Suppression
- First Metastasis Site Predicts Prostate Cancer-Specific Survival
- High Phosphorus Ups Risk of Kidney Transplant Failure, Death
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Anemia
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetes
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Hemodialysis
- Hyperphosphatemia
- Hypertension
- Hyperuricemia
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)
- Transplantation